Peptides: Half-Life and Stability

Half-life (t½) is the time required for plasma concentration of a peptide to decrease by 50%. For research peptides, understanding half-life is essential for designing rational dosing protocols — and explains why identical peptides with and without half-life modifications require fundamentally different dosing strategies.

What Determines Half-Life

Four primary mechanisms determine how quickly a peptide is cleared from circulation:

1. Peptidase cleavage — serum proteases and dipeptidyl peptidase IV (DPP-IV) are the main culprits for rapid clearance. GHRP-2 is a DPP-IV substrate, contributing to its 30-minute half-life.
2. Renal filtration — peptides below ~30 kDa are filtered by glomeruli; most research peptides (500–5000 Da) are freely filtered.
3. Route of administration — subcutaneous injection creates a tissue depot that releases peptide slowly, effectively extending the apparent half-life compared to IV bolus.
4. Structural modifications — acetylation, PEGylation, amidation, cyclization, and albumin-binding tags all protect against the mechanisms above.

Half-Life Reference Table

Peptide	Half-Life (subcut)	Key Half-Life Modifier	Practical Dosing Implication
GHRP-2	~30 min	None (DPP-IV substrate)	2–3x daily injection required for sustained effect
CJC-1295 (no-DAC / Mod GRF 1-29)	~30 min	None	Inject immediately before sleep (pulsatile GH peak)
CJC-1295 DAC	6–8 days	DAC albumin binding	Once-weekly injection; blunts pulsatile GH pattern
Ipamorelin	~2 h	None	1–3x daily; often stacked with CJC-1295 no-DAC
BPC-157	~4 h (estimated)	None	Once or twice daily; based on animal PK data
TB-500 (Thymosin β-4)	Days (variable)	Larger molecular weight (~4963 Da)	Typically dosed 2x weekly in protocols
GHK-Cu	Hours (topical)	Copper chelation may stabilize	Applied topically; injectable half-life not well characterized
Semaglutide	~7 days	C18 fatty acid + albumin binding	Once-weekly subcutaneous injection

Subcutaneous Depot Effect

The subcutaneous fat layer acts as a slow-release reservoir. After injection, the peptide forms a small depot at the injection site. Dissolution into interstitial fluid and then lymphatic/capillary uptake occurs over minutes to hours — meaningfully slower than IV delivery. This is why subcutaneous bioavailability estimates (85–95%) apply to overall absorption efficiency, not speed.

Acetylation and N-Terminal Protection

Adding an acetyl group (CH₃CO–) to the N-terminus blocks aminopeptidase attack at that end. Similarly, C-terminal amidation (–NH₂ instead of –COOH) prevents carboxypeptidase degradation. Many synthetic peptides incorporate both modifications to extend half-life without altering receptor binding characteristics [PMID 23253135].

DAC: How Albumin Binding Transforms CJC-1295

Native GHRH(1-44) has a plasma half-life of approximately 7 minutes. Mod GRF(1-29) with amino acid substitutions extends this to ~30 minutes. Adding the DAC maleimidoproprionic acid group — which spontaneously reacts with Cys-34 on albumin — extends it to 6–8 days [PMID 16968793]. The albumin-bound peptide is protected from DPP-IV, shielded from renal filtration (albumin MW is ~69,000 Da), and released slowly as albumin turns over. However, this continuous GHRH stimulation produces a sustained rather than pulsatile GH release pattern, which may have different physiological implications than the natural pulsatile secretion.

PEGylation

Polyethylene glycol (PEG) chains attached to peptides increase hydrodynamic radius, reducing renal filtration. PEGylated peptides are common in pharmaceutical development but are rarely found in research chemical supply chains, where DAC and N/C-terminal modifications are the more practical approaches.